MEKiAUTO: Phase 1/2 open-label study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the AUTOphagy inhibitor, hydroxychloroquine in KRAS-mutated advanced malignancies.
The purpose of this study is to determine how safe and effective the combination of atezolizumab, cobimetinib, and hydroxychloroquine is at treating KRAS-mutated advanced malignancies, and also to determine the maximum dose of this combination of drugs that can be tolerated by patients. This combination is thought to work by increasing the body's ability to attack tumors through its immune system.
Are you Eligible? (Inclusion Criteria)
- You have advanced cancer, such as pancreatic, colorectal, or non-small cell lung cancer, for which no curable options are available
- You are 18 years of age or older
- You are willing to use birth control for the duration of the study